HeartFlow today announced that it has appointed John Farquhar as chief operating officer, effective immediately.
Farquhar will be responsible for executing the strategic vision of the Redwood City, Calif.–based company — developer of the non-invasive HeartFlow FFRCT analysis.
“We are thrilled to add an executive of John’s caliber and accomplishments to the HeartFlow leadership team,” CEO and president John Stevens said in a news release. “In his new role, he will lead and provide strategic oversight of our key operational areas to ensure excellence and disciplined growth as HeartFlow continues to transform the diagnosis and management of coronary artery disease.”
Farquhar has more than 20 years of experience providing strategic oversight. He most recently served as VP and GM of Medtronic’s aortic business. He has also held numerous leadership roles for Medtronic’s cardiovascular and diabetes groups.
“I am excited to join an innovative, high-growth company with a compelling vision to change the paradigm for managing and treating heart disease,” Farquhar said. “I look forward to working with the leadership team at HeartFlow to democratize access to this incredible technology.”
HeartFlow recently announced that it is going public through a $2.8 billion SPAC merger with Longview Acquisition Corp.
